Physician profile
Vladimir Milo
NPI 1609848852
$2,787.95
in general payments reported to CMS, 2019-2025
26 companies · $92.17 in 2025
The $92.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $239 · 2021: $392 · 2022: $791 · 2023: $639 · 2024: $212 · 2025: $92.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $822.88 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $282.50 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $256.12 | 2021-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $237.18 | 2021-2024 | |
| Fresenius USA Marketing, INC. | $191.84 | 2019-2023 | Korsuva, Velphoro |
| Calliditas Therapeutics US INC. | $79.74 | 2022-2023 | Tarpeyo |
| E.R. Squibb & Sons, L.L.C. | $75.90 | 2019-2022 | |
| Daiichi Sankyo INC. | $75.14 | 2022-2023 | Injectafer |
| Aurinia Pharma U.S., INC. | $72.13 | 2022-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $71.71 | 2022-2023 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $71.48 | 2022-2025 | Farxiga |
| Travere Therapeutics, INC. | $69.07 | 2024 | |
| Portola Pharmaceuticals, LLC | $68.42 | 2019 | |
| Horizon Therapeutics Plc | $59.77 | 2023 | Krystexxa |
| Amgen INC. | $55.48 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.66 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $36.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.85 | 2023-2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $25.38 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.27 | 2022 | |
| Ardelyx, INC. | $22.83 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $20.23 | 2025 | |
| Akebia Therapeutics INC | $17.33 | 2025 | Vafseo |
| Shire North American Group INC | $16.81 | 2019 | |
| Shield Therapeutics INC | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Milo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.